Abbisko Cayman Limited

HK$6.36As of Sun 8 Nov 2026, 12:00 UTC
HKEX:2256Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 5Y CAGR (11.57%)
Div yield —
ROE (21.20%)
Biotechnology
Beta (5Y) 1.16
PE TTM —
TSR TTM (56.35%)
Mkt cap HK$4.209B
ROIC (301.05%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$7.17
12.76%
(10.67%)
Hold 12|3|7|5|3
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.10
0.10
0.10
0.10
12.72%
12.50%
13.56%
15.31%
Revenue¥M
384.4
400.7
423.5
411.2
(0.21%)
7.02%
13.93%
13.04%
Peers (US$536.9M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.198
(0.647)
(0.646)
EBIT/Intx
1.724
0.114
0.130
Own earn%
(33.63)
(20.49)
(11.03)
Sh yield%
30.12
41.56
38.15
Owners
Insiders/Inst%
7.75
34.20
Short interest%
2.90
SBC / revenue%
0.92
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
25
Op margin range%
16–27
$1 testx
0.4
Incr. ROIC%
4